Episindan 2 mg/ml IV Infusion

• As a single agent: 60-90 mg/m² 3-4 wkly.
• Max (total cumulative dose): 0.9-1 g/m².
• Palliative care: 12.5-25 mg/m² once wkly.

Adjuvant treatment in axillary-node positive breast cancer: Recommended starting doses: 100-120 mg/m² as a single dose on day 1 or as 2 divided doses on days 1 and 8 of each 28-day cycle. Repeat for 6 cycles.

Intravesical Local treatment of bladder carcinoma: As 0.1% soln: 50 mg/wk for 8 wk; reduce dose if chemical cystitis develops.

For carcinoma in-situ: 80 mg in 50 mL wkly.

For prevention of recurrence in patients who have undergone transurethral resection: 50 mg/wk for 4 wk, followed by 50 mg/mth for 11 mth; retain soln in the bladder for 1 hr during each administration.